Athira Pharma, Inc. Stock Price, News & Analysis

Athira Pharma (NASDAQ: ATHA) recently released a review paper emphasizing the urgent need for innovative treatments for Alzheimer’s disease, specifically highlighting the potential of fosgonimeton, a small molecule modulator of the HGF/MET system. Published in the Journal of Alzheimer’s Disease, the article discusses current drug development limitations and the necessity for novel research methodologies. Athira's clinical candidate is currently being evaluated in the Phase 2/3 LIFT-AD study, targeting mild-to-moderate Alzheimer’s disease, with enrollment expected to conclude by mid-2023 and topline results anticipated in early 2024.

Athira Pharma, Inc. (NASDAQ: ATHA) has promoted Kevin Church, Ph.D., to Chief Scientific Officer, recognizing his vital role in advancing the company’s research on neurodegenerative diseases. Dr. Church, who has been with Athira since 2016, previously served as Executive Vice President of Research and has been instrumental in exploring the HGF/MET pathway for potential therapies targeting Alzheimer's, Parkinson's, and other neurological disorders. His leadership is expected to strengthen the company’s innovative approach to restoring neuronal health.

Athira Pharma (NASDAQ: ATHA) provided a pipeline update, highlighting its ongoing Phase 2/3 LIFT-AD study for mild-to-moderate Alzheimer’s disease with expected topline data in early 2024. The study aims to investigate the candidate fosgonimeton for neuroprotective effects. Additionally, ATH-1105, targeting amyotrophic lateral sclerosis (ALS), is set for an IND filing in 2023. Athira reported a solid financial position with $260 million in cash as of September 30, 2022, reinforcing its capability to advance its development programs.

Athira Pharma (NASDAQ: ATHA) published preclinical data on December 20, 2022, highlighting the neuroprotective and cognitive-enhancing effects of fosgonimeton (ATH-1017). This research demonstrates fosgonimeton's potential in enhancing the HGF/MET neurotrophic system, crucial for addressing dementia and neurodegenerative diseases. The study shows that fosgonimeton promotes neuronal protection and cognitive improvement in various animal models affected by neurodegeneration. These findings support ongoing clinical development efforts targeting diseases like Alzheimer's and Parkinson's.

Athira Pharma (NASDAQ: ATHA) presented findings on ATH-1105, a small molecule positive modulator of the HGF/MET neurotrophic system, at the 33rd International Symposium on ALS/MND. In a TDP-43 mouse model of ALS, ATH-1105 demonstrated significant improvements in motor function, nerve function, and reductions in neurodegeneration markers. Treated mice showed better weight retention, enhanced motor skills, and reduced inflammation biomarkers. These results support ATH-1105 as a potential therapeutic candidate for ALS and possibly other neurodegenerative diseases.

Athira Pharma (NASDAQ: ATHA) announced a virtual R&D event titled “Enhancing the HGF/MET System to Fight Neurodegenerative Diseases,” scheduled for December 7, 2022, from 2:00 p.m. to 3:30 p.m. EST. The event will showcase preclinical and clinical data supporting the potential of HGF/MET in treating neurodegenerative diseases. Key executives, including Mark Litton, will present updates on Athira’s therapeutic pipeline, followed by an interactive Q&A session. Interested participants can pre-register and access the live webcast on Athira's website.

Athira Pharma (NASDAQ: ATHA) presented new biomarker data from the completed ACT-AD Phase 2 study of fosgonimeton, showing significant reductions in biomarkers of neurodegeneration (NfL) and neuroinflammation (GFAP) that correlate with improved clinical outcomes in mild-to-moderate Alzheimer’s patients. Fosgonimeton treatment also demonstrated directional improvements in Alzheimer’s protein pathologies compared to placebo. The company continues to progress in its Phase 2/3 LIFT-AD study, aiming for topline data release in early 2024.

Athira Pharma announced positive preclinical data for its small molecule, ATH-1105, showing neuroprotective effects and improved motor and nerve function in a TDP-43 mouse model of ALS. The findings will be presented at the upcoming Motor Neurone Disease Association’s 33rd International Symposium on ALS/MND, scheduled for December 6-9, 2022. This research highlights ATH-1105's therapeutic potential in neurodegenerative conditions, aligning with Athira's mission to restore neuronal health.

Athira Pharma, Inc. (NASDAQ: ATHA) announced promising preclinical results at Neuroscience 2022 regarding fosgonimeton, a small molecule aimed at treating Parkinson’s disease and diabetic neuropathy. The findings indicate that fosgonimeton promotes neuroprotection and enhances motor performance in Parkinson’s models. Additionally, HGF/MET modulators ATH-1018 and ATH-1020 showed significant pain reduction in diabetic neuropathy, sustaining effects even after washout periods. These developments highlight Athira's commitment to advancing treatments for neurodegeneration and pain management.